Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
117%(7 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_3
1
14%
Ph phase_4
3
43%
Ph phase_2
3
43%

Phase Distribution

0

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
1(14.3%)
Phase 4Post-market surveillance
3(42.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(6)
Terminated(1)

Detailed Status

Completed6
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (42.9%)
Phase 31 (14.3%)
Phase 43 (42.9%)

Trials by Status

completed686%
terminated114%

Recent Activity

0 active trials
Showing 5 of 7
terminatedphase_2

To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy

NCT01302899
completedphase_2

Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure

NCT00923156
completedphase_4

Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal

NCT00865020
completedphase_4

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

NCT00631917
completedphase_3

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone

NCT00777946
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT01302899Phase 2

To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy

Terminated
NCT00923156Phase 2

Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure

Completed
NCT00865020Phase 4

Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal

Completed
NCT00631917Phase 4

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

Completed
NCT00777946Phase 3

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone

Completed
NCT00819767Phase 2

Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise

Completed
NCT00654875Phase 4

Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7